Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilofexor (Primary) ; Firsocostat (Primary) ; Semaglutide (Primary)
  • Indications Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms WAYFIND
  • Sponsors Gilead Sciences

Most Recent Events

  • 28 Oct 2025 According to a Novo Nordisk media release, data from this study will be presented in an Oral presentation (0148) on Sunday 9 November at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting 2025, from 7 to 11 November in Washington D.C., U.S.
  • 08 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 17 Jul 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top